PEG-EPO is under clinical development by Zydus Lifesciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect PEG-EPO’s likelihood of approval (LoA) and phase transition for Anemia in Chronic Kidney Disease (Renal Anemia) took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PEG-EPO Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
PEG-EPO (pegylated erythropoietin) is under development for the treatment anaemia of chronic renal failure. It is administered subcutaneously. It acts by targeting the erythropoietin receptor. The drug candidate is based on protein pegylation technology. It was also under development for the treatment of beta-thalassemia
Zydus Lifesciences overview
Zydus Lifesciences formerly Cadila Healthcare Ltd is an integrated global healthcare provider. It discovers, develops, manufactures and commercializes various healthcare products. The company’s product portfolio includes active pharmaceutical ingredients (APIs), formulations, wellness and animal health products. Zydus Lifesciences products find application in the treatment of diseases in the therapeutic areas of gastrointestinal, cardiovascular, respiratory, pain management, cancer, inflammation, neurology, and women’s health, among others. It conducts research to develop biologics, biosimilars, vaccines and new chemical entities. The company has manufacturing facilities in Gujarat, Goa, Maharashtra, Sikkim and Himachal Pradeshin India; Brazil and the US. It has presence in the US, Europe, South Africa, Japan, Brazil, and other emerging markets. Zydus Lifesciences is headquartered in Ahmedabad, Gujarat, India.
Quick View PEG-EPO LOA Data
|Highest Development Stage|